BIIB Insider Activity: William Hawkins Acquires 2,370 Shares

Rhea-AI Filing Summary

Biogen Inc. (BIIB) has filed a Form 4 indicating that director William A. Hawkins acquired 2,370 shares of the company’s common stock on 06/17/2025. The transaction is coded “A” (acquisition) and carries a reported price of $0, suggesting the shares were granted rather than purchased on the open market. Following the transaction, Hawkins’ direct beneficial ownership stands at 8,860 shares.

The filing confirms Hawkins’ role as a director and notes the document was signed on 06/18/2025 by attorney-in-fact Wendell Taylor. No derivative security activity or additional transactions were reported.

Positive

• Director William A. Hawkins increased his direct holdings by 2,370 shares, raising total ownership to 8,860 shares.

Negative

• None.

Insights

Securities Analyst

TL;DR: Small insider share increase; signal is mildly positive but not materially impactful.

The Form 4 shows director William A. Hawkins adding 2,370 BIIB shares, bringing his direct holdings to 8,860. The $0 price indicates a grant, likely automatic board compensation, which limits predictive value regarding future share performance. Nonetheless, the greater alignment of a board member’s interests with shareholders is generally viewed constructively. Given the modest size relative to Biogen’s ~145 million shares outstanding, market impact should be minimal.

Corporate Governance Expert

TL;DR: Routine equity award increases board alignment; governance status unchanged.

This filing documents a standard equity grant to a non-executive director. Such grants are common practice to align board incentives with long-term shareholder value. There are no red flags: the form is timely, correctly signed, and contains no dispositions. From a governance lens, the transaction is benign and supportive, but not a catalyst for strategic change.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HAWKINS WILLIAM A

(Last) (First) (Middle)

BIOGEN INC.

225 BINNEY ST.

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2025		A		2,370	A	$0	8,860	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Wendell Taylor, Attorney in Fact for William Allen Hawkins III	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Biogen (BIIB) shares did director William A. Hawkins acquire?

He acquired 2,370 shares of common stock.

What is Hawkins’ total Biogen share ownership after the transaction?

After the acquisition, he directly owns 8,860 shares.

What transaction code is listed in the Form 4 for BIIB?

The filing lists transaction code "A", indicating an acquisition.

At what price were the shares reported as acquired?

The reported acquisition price is $0 per share.

When was the Form 4 for William A. Hawkins signed and filed?

It was signed on 06/18/2025 and covers a transaction dated 06/17/2025.